In Q1 2025, Allakos Inc. reported a net loss of $26.2 million, a significant improvement from the $71.15 million loss in the same quarter the previous year. The company implemented major restructuring efforts, including workforce reductions and discontinuation of its AK006 program, to streamline operations and reduce expenses.

Allakos reported a net income of $0.4 million for the fourth quarter of 2024, a significant improvement from a net loss of $62.6 million in the same period last year, primarily driven by a $23.9 million gain on lease amendment. The company ended the quarter with $80.8 million in cash, cash equivalents, and investments.

Allakos reported a net loss of $18.4 million for the third quarter of 2024, with cash, cash equivalents, and investments totaling $92.7 million. Research and development expenses were $10.9 million, and general and administrative expenses were $8.9 million.

Allakos reported a net loss of $26.7 million for the second quarter of 2024. The company ended the quarter with $123.1 million in cash, cash equivalents and investments.

Allakos reported a net loss of $71.1 million for the first quarter of 2024. The company's cash, cash equivalents, and investments totaled $139.3 million, reflecting a decrease of $31.5 million during the quarter. Research and development expenses were $34.8 million, while general and administrative expenses amounted to $10.9 million.

Allakos reported a net loss of $62.6 million for the fourth quarter of 2023. The company halted lirentelimab-related development to focus on AK006 clinical development.

Allakos reported a net loss of $45.6 million for the third quarter of 2023, compared to a net loss of $30.8 million for the third quarter of 2022. Research and development expenses were $36.7 million, an increase of $18.3 million compared to the same period in 2022. The company ended the quarter with $193.9 million in cash, cash equivalents and investments.

Allakos reported a net loss of $35.1 million in the second quarter of 2023, compared to a net loss of $49.1 million in the second quarter of 2022. The company's cash, cash equivalents, and investments totaled $221.1 million at the end of the quarter.

Allakos reported a net loss of $42.4 million in the first quarter of 2023, compared to a net loss of $197.0 million for the same period in 2022. Research and development expenses were $33.1 million, significantly lower than the $176.8 million reported in the first quarter of 2022 due to cost reduction efforts. The company ended the quarter with $252.6 million in cash, cash equivalents and investments.

Allakos reported a net loss of $43.0 million for the fourth quarter of 2022, compared to a net loss of $94.4 million for the same period in 2021. The company's research and development expenses decreased significantly due to cost-cutting efforts.

Allakos reported a net loss of $30.8 million for the third quarter of 2022, compared to a net loss of $62.7 million for the same period in 2021. The company's research and development expenses were $18.4 million, including a $12.2 million benefit from raw material disposals, and general and administrative expenses were $13.0 million.

Allakos reported a net loss of $49.1 million in the second quarter of 2022, compared to a net loss of $57.2 million in the second quarter of 2021. The company's research and development expenses were $34.4 million, and general and administrative expenses were $14.7 million.

Allakos reported a net loss of $197.0 million in the first quarter of 2022, compared to a net loss of $55.6 million in the same period in 2021. The increased loss was primarily due to settlement costs related to exiting contractual obligations and workforce reduction.

Allakos reported a net loss of $94.4 million in the fourth quarter of 2021, compared to a net loss of $44.3 million in the same period in 2020. The company ended the quarter with $424.2 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $62.7 million in the third quarter of 2021, compared to a net loss of $42.1 million in the same period in 2020. The company ended the quarter with $505.6 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $57.2 million for the second quarter of 2021, compared to $39.3 million in the same period in 2020. The company ended the quarter with $559.7 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $55.6 million in the first quarter of 2021, compared to $27.8 million in the same period in 2020. The company ended the quarter with $615.9 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $44.3 million in the fourth quarter of 2020, compared to a net loss of $24.6 million in the same period in 2019. The company ended the year with $659.0 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $42.1 million in the third quarter of 2020, compared to $21.7 million in the same period in 2019. The company ended the quarter with $419.8 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $39.3 million in the second quarter of 2020, compared to $19.1 million in the same period in 2019. The company ended the quarter with $454.9 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $27.8 million in the first quarter of 2020, compared to $20.0 million in the same period in 2019. The company ended the quarter with $479.8 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $24.6 million in the fourth quarter of 2019, compared to a net loss of $14.5 million in the same period in 2018. The company ended the year with $495.9 million in cash, cash equivalents and marketable securities.